

Matteo Bassetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2464371/publications.pdf>

Version: 2024-02-01

411
papers

23,630
citations

9254

74
h-index

11601

135
g-index

421
all docs

421
docs citations

421
times ranked

21164
citing authors

#	ARTICLE	IF	CITATIONS
1	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	2.9	1,429
2	Predictors of Mortality in Bloodstream Infections Caused by <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> : Importance of Combination Therapy. <i>Clinical Infectious Diseases</i> , 2012, 55, 943-950.	2.9	855
3	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?. <i>Clinical Infectious Diseases</i> , 2014, 58, 1072-1083.	2.9	843
4	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e149-e162.	4.6	586
5	Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 984.	3.8	538
6	Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 395-404.	5.2	527
7	Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#. <i>Intensive Care Medicine</i> , 2020, 46, 1127-1153.	3.9	504
8	How to manage <i>Pseudomonas aeruginosa</i> infections. <i>Drugs in Context</i> , 2018, 7, 1-18.	1.0	491
9	Infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : differences in therapy and mortality in a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2133-2143.	1.3	434
10	Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 226-240.	4.6	411
11	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1752-1760.	15.2	353
12	New antibiotics for bad bugs: where are we?. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2013, 12, 22.	1.7	339
13	European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European) Tj ETQq1 1 0.784314 rg324 Overl	1.7	324
14	Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant <i>Acinetobacter baumannii</i> : A Multicenter, Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2013, 57, 349-358.	2.9	322
15	Effect and Safety of Meropenem+Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. <i>Infectious Diseases and Therapy</i> , 2018, 7, 439-455.	1.8	313
16	The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13209.	1.7	285
17	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.	3.9	278
18	Epidemiological trends in nosocomial candidemia in intensive care. <i>BMC Infectious Diseases</i> , 2006, 6, 21.	1.3	266

#	ARTICLE	IF	CITATIONS
19	Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by <i>Klebsiella pneumoniae</i> Carbapenemase-producing <i>K. pneumoniae</i> . <i>Clinical Infectious Diseases</i> , 2019, 68, 355-364.	2.9	265
20	Personal protective equipment and intensive care unit healthcare worker safety in the COVID-19 era (PPE-SAFE): An international survey. <i>Journal of Critical Care</i> , 2020, 59, 70-75.	1.0	234
21	Treatment of Infections Due to MDR Gram-Negative Bacteria. <i>Frontiers in Medicine</i> , 2019, 6, 74.	1.2	211
22	A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. <i>Intensive Care Medicine</i> , 2014, 40, 839-845.	3.9	209
23	Bloodstream infections in critically ill patients with COVID-19. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13319.	1.7	203
24	Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. <i>Intensive Care Medicine</i> , 2017, 43, 1464-1475.	3.9	199
25	Epidemiology, Species Distribution, Antifungal Susceptibility, and Outcome of Candidemia across Five Sites in Italy and Spain. <i>Journal of Clinical Microbiology</i> , 2013, 51, 4167-4172.	1.8	176
26	A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. <i>Intensive Care Medicine</i> , 2013, 39, 2092-2106.	3.9	169
27	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e246-e257.	4.6	167
28	A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. <i>Intensive Care Medicine</i> , 2015, 41, 1601-1610.	3.9	165
29	Epidemiology, Species Distribution, Antifungal Susceptibility and Outcome of Nosocomial Candidemia in a Tertiary Care Hospital in Italy. <i>PLoS ONE</i> , 2011, 6, e24198.	1.1	164
30	Bloodstream infections in critically ill patients: an expert statement. <i>Intensive Care Medicine</i> , 2020, 46, 266-284.	3.9	159
31	Diagnosing COVID-19-associated pulmonary aspergillosis. <i>Lancet Microbe</i> , The, 2020, 1, e53-e55.	3.4	158
32	Rationalizing antimicrobial therapy in the ICU: a narrative review. <i>Intensive Care Medicine</i> , 2019, 45, 172-189.	3.9	155
33	2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. <i>World Journal of Emergency Surgery</i> , 2018, 13, 58.	2.1	154
34	Identifying Patients Harboring Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae on Hospital Admission: Derivation and Validation of a Scoring System. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3485-3490.	1.4	137
35	Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. <i>Intensive Care Medicine</i> , 2015, 41, 776-795.	3.9	133
36	Task force on management and prevention of <i>Acinetobacter baumannii</i> infections in the ICU. <i>Intensive Care Medicine</i> , 2015, 41, 2057-2075.	3.9	133

#	ARTICLE	IF	CITATIONS
37	Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology. <i>Clinical Microbiology and Infection</i> , 2022, 28, 580-587.	2.8	133
38	Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). <i>World Journal of Emergency Surgery</i> , 2016, 11, 33.	2.1	130
39	Ceftazidime-Avibactam Use for <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1664-1676.	2.9	130
40	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 196-207.	1.3	129
41	Distinct phenotypes require distinct respiratory management strategies in severe COVID-19. <i>Respiratory Physiology and Neurobiology</i> , 2020, 279, 103455.	0.7	129
42	ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. <i>Intensive Care Medicine</i> , 2019, 45, 789-805.	3.9	127
43	Intensive care medicine research agenda on invasive fungal infection in critically ill patients. <i>Intensive Care Medicine</i> , 2017, 43, 1225-1238.	3.9	123
44	Multidrug-resistant <i>Klebsiella pneumoniae</i> : challenges for treatment, prevention and infection control. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 749-761.	2.0	123
45	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. <i>Critical Care</i> , 2019, 23, 219.	2.5	123
46	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology</i> , The, 2021, 3, e690-e697.	2.2	121
47	Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing <i>Klebsiella pneumoniae</i> . <i>Critical Care</i> , 2020, 24, 29.	2.5	121
48	Ceftolozane/tazobactam for the treatment of serious <i>Pseudomonas aeruginosa</i> infections: a multicentre nationwide clinical experience. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 408-415.	1.1	120
49	Epidemiology and Outcome of Fungemia in a Cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). <i>Clinical Infectious Diseases</i> , 2015, 61, 324-331.	2.9	117
50	The management of multidrug-resistant Enterobacteriaceae. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 583-594.	1.3	112
51	EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. <i>Clinical Infectious Diseases</i> , 2021, 72, S121-S127.	2.9	109
52	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. <i>Critical Care</i> , 2015, 19, 33.	2.5	108
53	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021, 47, 819-834.	3.9	106
54	Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 58, 325-331.	0.8	104

#	ARTICLE	IF	CITATIONS
55	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. <i>Intensive Care Medicine</i> , 2017, 43, 1187-1197.	3.9	103
56	Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. <i>Intensive Care Medicine</i> , 2018, 44, 189-196.	3.9	101
57	Invasive mould infections in the ICU setting: complexities and solutions. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i39-i47.	1.3	100
58	Ceftolozane/tazobactam: place in therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 307-320.	2.0	100
59	New treatment options against gram-negative organisms. <i>Critical Care</i> , 2011, 15, 215.	2.5	97
60	Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). <i>Intensive Care Medicine</i> , 2020, 46, 245-265.	3.9	97
61	Why is community-associated MRSA spreading across the world and how will it change clinical practice?. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, S15-S19.	1.1	95
62	Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug-resistant/extensively drug-resistant/pandrug-resistant bacteria. <i>Current Opinion in Critical Care</i> , 2018, 24, 385-393.	1.6	95
63	Advances in antibiotic therapy in the critically ill. <i>Critical Care</i> , 2016, 20, 133.	2.5	94
64	Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 555.	1.0	93
65	Clinical and Therapeutic Aspects of Candidemia: A Five Year Single Centre Study. <i>PLoS ONE</i> , 2015, 10, e0127534.	1.1	90
66	Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 330-340.	4.6	88
67	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. <i>Critical Care</i> , 2014, 18, R99.	2.5	87
68	Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults. <i>Anesthesiology</i> , 2017, 126, 890-908.	1.3	87
69	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. <i>PLoS ONE</i> , 2020, 15, e0237831.	1.1	85
70	Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1537-1544.	2.8	84
71	Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 625-629.	1.3	83
72	Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. <i>Critical Care</i> , 2016, 20, 125.	2.5	83

#	ARTICLE	IF	CITATIONS
73	Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update. <i>Journal of Chemotherapy</i> , 2017, 29, 197-214.	0.7	81
74	Raising concerns about the Sepsis-3 definitions. <i>World Journal of Emergency Surgery</i> , 2018, 13, 6.	2.1	81
75	Drug treatment for multidrug-resistant <i>Acinetobacter baumannii</i> infections. <i>Future Microbiology</i> , 2008, 3, 649-660.	1.0	79
76	Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1386-1395.	1.3	79
77	Bacterial and fungal superinfections in critically ill patients with COVID-19. <i>Intensive Care Medicine</i> , 2020, 46, 2071-2074.	3.9	79
78	Predictive Models for Identification of Hospitalized Patients Harboring KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3514-3520.	1.4	75
79	Inhaled Liposomal Antimicrobial Delivery in Lung Infections. <i>Drugs</i> , 2020, 80, 1309-1318.	4.9	75
80	Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e3647-e3655.	2.9	75
81	New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. <i>Current Opinion in Critical Care</i> , 2015, 21, 402-411.	1.6	71
82	Bloodstream infections in the Intensive Care Unit. <i>Virulence</i> , 2016, 7, 267-279.	1.8	71
83	Italian nationwide survey on <i>Pseudomonas aeruginosa</i> from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 664-671.	1.3	71
84	Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors. <i>Journal of Clinical Medicine</i> , 2020, 9, 2780.	1.0	71
85	The current treatment landscape: candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, ii13-ii22.	1.3	69
86	What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, i14-i25.	1.3	69
87	Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 585-596.	2.0	68
88	Panton-Valentine leukocidin-positive <i>Staphylococcus aureus</i> : a position statement from the International Society of Chemotherapy. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 16-25.	1.1	68
89	Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales. <i>Antibiotics</i> , 2020, 9, 71.	1.5	68
90	Bloodstream infections caused by carbapenem-resistant <i>Acinetobacter baumannii</i> : Clinical features, therapy and outcome from a multicenter study. <i>Journal of Infection</i> , 2019, 79, 130-138.	1.7	67

#	ARTICLE	IF	CITATIONS
91	Characteristics of Staphylococcus aureus Bacteraemia and Predictors of Early and Late Mortality. PLoS ONE, 2017, 12, e0170236.	1.1	67
92	High-dose daptomycin in documented Staphylococcus aureus infections. International Journal of Antimicrobial Agents, 2010, 36, 459-461.	1.1	66
93	Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?. International Journal of Antimicrobial Agents, 2017, 49, 255-258.	1.1	65
94	Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections. Expert Review of Anti-Infective Therapy, 2017, 15, 55-65.	2.0	64
95	The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient—A Case Study. Open Forum Infectious Diseases, 2021, 8, ofab217.	0.4	64
96	Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies. Journal of Global Antimicrobial Resistance, 2021, 25, 268-281.	0.9	62
97	Infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : differences in therapy and mortality in a multicentre study—authors' response. Journal of Antimicrobial Chemotherapy, 2015, 70, 2922-2922.	1.3	60
98	Role of pharmacists in antimicrobial stewardship programmes. International Journal of Clinical Pharmacy, 2018, 40, 948-952.	1.0	60
99	Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Annals of Intensive Care, 2016, 6, 35.	2.2	59
100	Computed tomography assessment of PEEP-induced alveolar recruitment in patients with severe COVID-19 pneumonia. Critical Care, 2021, 25, 81.	2.5	59
101	Risk Factors and Outcomes of Endocarditis Due to Non-HACEK Gram-Negative Bacilli: Data from the Prospective Multicenter Italian Endocarditis Study Cohort. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	56
102	Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. International Journal of Antimicrobial Agents, 2018, 51, 244-248.	1.1	55
103	New antibiotics for ventilator-associated pneumonia. Current Opinion in Infectious Diseases, 2018, 31, 177-186.	1.3	54
104	Timing of antibiotic therapy in the ICU. Critical Care, 2021, 25, 360.	2.5	54
105	Current Status of Newer Carbapenems. Current Medicinal Chemistry, 2009, 16, 564-575.	1.2	53
106	Clinical Performance of the (1,3)- β -D-Glucan Assay in Early Diagnosis of Nosocomial Candida Bloodstream Infections. Vaccine Journal, 2011, 18, 2113-2117.	3.2	53
107	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project. Mycoses, 2019, 62, 310-319.	1.8	53
108	Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy. Journal of Nephrology, 2021, 34, 173-183.	0.9	52

#	ARTICLE	IF	CITATIONS
109	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. <i>Intensive Care Medicine</i> , 2017, 43, 509-518.	3.9	51
110	Candida auris Candidemia in Critically Ill, Colonized Patients: Cumulative Incidence and Risk Factors. <i>Infectious Diseases and Therapy</i> , 2022, 11, 1149-1160.	1.8	51
111	<i>In Vitro</i> Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	50
112	Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, ii25-ii35.	1.3	49
113	Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa139.	0.4	49
114	Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?. <i>Critical Care</i> , 2015, 20, 19.	2.5	48
115	Diagnostic and therapeutic approach to infectious diseases in solid organ transplant recipients. <i>Intensive Care Medicine</i> , 2019, 45, 573-591.	3.9	48
116	Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum β -lactamase-producing organisms in an intensive care unit. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 433-435.	1.3	47
117	Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19. <i>Annals of Internal Medicine</i> , 2022, 175, 1126-1134.	2.0	47
118	Challenges and Solution of Invasive Aspergillosis in Non-neutropenic Patients: A Review. <i>Infectious Diseases and Therapy</i> , 2018, 7, 17-27.	1.8	46
119	Neurological Manifestations of Severe SARS-CoV-2 Infection: Potential Mechanisms and Implications of Individualized Mechanical Ventilation Settings. <i>Frontiers in Neurology</i> , 2020, 11, 845.	1.1	46
120	A Systematic Review of the Effect of Delayed Appropriate Antibiotic Treatment on the Outcomes of Patients With Severe Bacterial Infections. <i>Chest</i> , 2020, 158, 929-938.	0.4	46
121	Isavuconazole shortens the QTc interval. <i>Mycoses</i> , 2018, 61, 256-260.	1.8	45
122	Procalcitonin levels in candidemia versus bacteremia: a systematic review. <i>Critical Care</i> , 2019, 23, 190.	2.5	45
123	Early effects of ventilatory rescue therapies on systemic and cerebral oxygenation in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome: a prospective observational study. <i>Critical Care</i> , 2021, 25, 111.	2.5	45
124	Bench-to-bedside review: Therapeutic management of invasive candidiasis in the intensive care unit. <i>Critical Care</i> , 2010, 14, 244.	2.5	44
125	Development of novel antibacterial drugs to combat multiple resistant organisms. <i>Langenbeck's Archives of Surgery</i> , 2015, 400, 153-165.	0.8	44
126	Management of carbapenem resistant <i>Klebsiella pneumoniae</i> infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement. <i>Haematologica</i> , 2015, 100, e373-e376.	1.7	44

#	ARTICLE	IF	CITATIONS
127	Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	44
128	Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, iv23-iv37.	1.3	44
129	Chest physiotherapy: An important adjuvant in critically ill mechanically ventilated patients with COVID-19. <i>Respiratory Physiology and Neurobiology</i> , 2020, 282, 103529.	0.7	43
130	Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity. <i>PLoS Pathogens</i> , 2021, 17, e1009448.	2.1	43
131	Diagnosis and treatment of COVID-19 associated pulmonary aspergillosis in critically ill patients: results from a European confederation of medical mycology registry. <i>Intensive Care Medicine</i> , 2021, 47, 1158-1160.	3.9	43
132	Tigecycline use in serious nosocomial infections: a drug use evaluation. <i>BMC Infectious Diseases</i> , 2010, 10, 287.	1.3	42
133	Will new antimicrobials overcome resistance among Gram-negatives?. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 909-922.	2.0	42
134	Eravacycline for the treatment of intra-abdominal infections. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1575-1584.	1.9	42
135	Ceftobiprole: drug evaluation and place in therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 689-698.	2.0	42
136	Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens. <i>Future Microbiology</i> , 2014, 9, 1053-1069.	1.0	41
137	Screening for carriage of carbapenem-resistant Enterobacteriaceae in settings of high endemicity: a position paper from an Italian working group on CRE infections. <i>Antimicrobial Resistance and Infection Control</i> , 2019, 8, 136.	1.5	41
138	Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant <i>Acinetobacter baumannii</i> : A Prospective, Observational Study. <i>Infectious Diseases and Therapy</i> , 2021, 10, 187-200.	1.8	41
139	Hot topics in the diagnosis and management of skin and soft-tissue infections. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 19-26.	1.1	40
140	Changes in the relative prevalence of candidaemia due to non- <i>Candida albicans</i> <i>Candida</i> species in adult inpatients: A systematic review, meta-analysis and meta-regression. <i>Mycoses</i> , 2020, 63, 334-342.	1.8	40
141	Critical issues for <i>Klebsiella pneumoniae</i> KPC-carbapenemase producing <i>K. pneumoniae</i> infections: a critical agenda. <i>Future Microbiology</i> , 2015, 10, 283-294.	1.0	39
142	Intratracheal Administration of Antimicrobial Agents in Mechanically Ventilated Adults: An International Survey on Delivery Practices and Safety. <i>Respiratory Care</i> , 2016, 61, 1008-1014.	0.8	39
143	Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1711-1718.	0.9	39
144	Lung distribution of gas and blood volume in critically ill COVID-19 patients: a quantitative dual-energy computed tomography study. <i>Critical Care</i> , 2021, 25, 214.	2.5	39

#	ARTICLE	IF	CITATIONS
145	Novel β -lactam antibiotics and inhibitor combinations. Expert Opinion on Investigational Drugs, 2008, 17, 285-296.	1.9	38
146	Antibiotic stewardship challenges in the management of community-acquired infections for prevention of escalating antibiotic resistance. Journal of Global Antimicrobial Resistance, 2014, 2, 245-253.	0.9	37
147	Rational approach in the management of Pseudomonas aeruginosa infections. Current Opinion in Infectious Diseases, 2018, 31, 578-586.	1.3	37
148	Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance. Antibiotics, 2020, 9, 632.	1.5	37
149	Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. International Journal of Antimicrobial Agents, 2022, 60, 106633.	1.1	37
150	Post-operative abdominal infections: epidemiology, operational definitions, and outcomes. Intensive Care Medicine, 2020, 46, 163-172.	3.9	36
151	Neurological Complications and Noninvasive Multimodal Neuromonitoring in Critically Ill Mechanically Ventilated COVID-19 Patients. Frontiers in Neurology, 2020, 11, 602114.	1.1	36
152	Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). International Journal of Antimicrobial Agents, 2022, 60, 106611.	1.1	36
153	Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study. Journal of Antimicrobial Chemotherapy, 2019, 74, 3588-3595.	1.3	35
154	High prevalence of olfactory and taste disorder during SARS-CoV-2 infection in outpatients. Journal of Medical Virology, 2020, 92, 2310-2311.	2.5	35
155	How to manage aspergillosis in non-neutropenic intensive care unit patients. Critical Care, 2014, 18, 458.	2.5	34
156	Nosocomial candidemia in patients admitted to medicine wards compared to other wards: a multicentre study. Infection, 2016, 44, 747-755.	2.3	34
157	Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. Transplantation Direct, 2017, 3, e156.	0.8	34
158	Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 333-339.	2.0	32
159	Early Detection of Sepsis With Machine Learning Techniques: A Brief Clinical Perspective. Frontiers in Medicine, 2021, 8, 617486.	1.2	32
160	Pseudomonas aeruginosa Serious Infections: Mono or Combination Antimicrobial Therapy?. Current Medicinal Chemistry, 2008, 15, 517-522.	1.2	31
161	The role of methicillin-resistant Staphylococcus aureus in skin and soft tissue infections. Current Opinion in Infectious Diseases, 2017, 30, 150-157.	1.3	31
162	Hot topics in necrotising skin and soft tissue infections. International Journal of Antimicrobial Agents, 2018, 52, 1-10.	1.1	31

#	ARTICLE	IF	CITATIONS
163	Efficacy and Safety of Meropenem+Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis. <i>Advances in Therapy</i> , 2019, 36, 1771-1777.	1.3	31
164	Early and Polyantigenic CD4 T Cell Responses Correlate with Mild Disease in Acute COVID-19 Donors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7155.	1.8	31
165	Delafloxacin for the treatment of respiratory and skin infections. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 433-442.	1.9	30
166	Role of procalcitonin in bacteremic patients and its potential use in predicting infection etiology. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 99-105.	2.0	30
167	Therapeutic Potential of the Gut Microbiota in the Management of Sepsis. <i>Critical Care</i> , 2020, 24, 105.	2.5	30
168	Safety profiles of old and new antimicrobials for the treatment of MRSA infections. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 467-481.	1.0	29
169	When antibiotic treatment fails. <i>Intensive Care Medicine</i> , 2018, 44, 73-75.	3.9	29
170	The role of biofilm forming on mortality in patients with candidemia: a study derived from real world data. <i>Infectious Diseases</i> , 2018, 50, 214-219.	1.4	29
171	Use of colistin in adult patients: A cross-sectional study. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 20, 43-49.	0.9	29
172	Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Clinical Infectious Diseases</i> , 2020, 71, 1799-1801.	2.9	28
173	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Infectious Diseases and Therapy</i> , 2021, 10, 1837-1885.	1.8	28
174	Successful treatment of methicillin-resistant <i>Staphylococcus aureus</i> endocarditis with linezolid. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 83-84.	1.1	27
175	Antimicrobial resistance and treatment: an unmet clinical safety need. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 669-680.	1.0	27
176	The role of new β -lactamase inhibitors in gram-negative infections. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 638-646.	1.3	27
177	All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 707-719.	2.0	27
178	Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on <i>Staphylococcus aureus</i> . <i>Clinical Infectious Diseases</i> , 2015, 60, 787-796.	2.9	26
179	The ideal patient profile for new beta-lactam/beta-lactamase inhibitors. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 587-593.	1.3	26
180	Hot topics on vertebral osteomyelitis from the International Society of Antimicrobial Chemotherapy. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 125-133.	1.1	26

#	ARTICLE	IF	CITATIONS
181	The global challenge of <i>Candida auris</i> in the intensive care unit. <i>Critical Care</i> , 2019, 23, 150.	2.5	26
182	The role of fosfomycin for multidrug-resistant gram-negative infections. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 617-625.	1.3	26
183	Induction of ketosis as a potential therapeutic option to limit hyperglycemia and prevent cytokine storm in COVID-19. <i>Nutrition</i> , 2020, 79-80, 110967.	1.1	26
184	Nebulization of antimicrobial agents in mechanically ventilated adults in 2017: an international cross-sectional survey. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 785-794.	1.3	25
185	The role of dalbavancin in skin and soft tissue infections. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 141-147.	1.3	25
186	–Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens â€œ The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study–. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 3607-3623.	1.1	25
187	How to manage KPC infections. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612091204.	1.1	25
188	Mould Infections of Traumatic Wounds: A Brief Narrative Review. <i>Infectious Diseases and Therapy</i> , 2020, 9, 1-15.	1.8	25
189	Therapeutic options for difficult-to-treat <i>Acinetobacter baumannii</i> infections: a 2020 perspective. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 167-177.	0.9	25
190	Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, ii15-ii24.	1.3	24
191	The safety of treatment options for acute bacterial skin and skin structure infections. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 635-650.	1.0	24
192	Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. <i>Clinical Infectious Diseases</i> , 2019, 69, 1912-1918.	2.9	24
193	Characterization of T lymphocytes in severe COVID-19 patients. <i>Journal of Medical Virology</i> , 2021, 93, 5608-5613.	2.5	24
194	Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2585-2586.	1.3	23
195	<i>Candida</i> endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian Study of Endocarditis. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 807-818.	2.0	23
196	Diagnosis and Treatment of Candidemia in the Intensive Care Unit. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 524-539.	0.8	23
197	Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure. <i>Cell Reports Medicine</i> , 2022, 3, 100560.	3.3	23
198	Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 875-885.	2.0	22

#	ARTICLE	IF	CITATIONS
199	Antimicrobial stewardship in ICUs during the COVID-19 pandemic: back to the 90s?. <i>Intensive Care Medicine</i> , 2021, 47, 104-106.	3.9	22
200	Enterococcal bloodstream infections in critically ill patients with COVID-19: a case series. <i>Annals of Medicine</i> , 2021, 53, 1779-1786.	1.5	22
201	Current antibiotic management of prosthetic joint infections in Italy: the "Udine strategy"™. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, i41-i45.	1.3	21
202	Focus on antimicrobial use in the era of increasing antimicrobial resistance in ICU. <i>Intensive Care Medicine</i> , 2016, 42, 955-958.	3.9	21
203	Higher fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) uptake in tuberculous compared to bacterial spondylodiscitis. <i>Skeletal Radiology</i> , 2017, 46, 777-783.	1.2	21
204	Independent risk factors for mortality in critically ill patients with candidemia on Italian Internal Medicine Wards. <i>Internal and Emergency Medicine</i> , 2018, 13, 199-204.	1.0	21
205	Role of procalcitonin in predicting etiology in bacteremic patients: Report from a large single-center experience. <i>Journal of Infection and Public Health</i> , 2020, 13, 40-45.	1.9	21
206	Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 4697-4711.	1.1	21
207	Challenges and research priorities to progress the impact of antimicrobial stewardship. <i>Drugs in Context</i> , 2019, 8, 1-15.	1.0	21
208	New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, 43, 280-294.	0.8	21
209	Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, ii37-ii44.	1.3	20
210	Managing skin and soft-tissue infection and nosocomial pneumonia caused by MRSA: a 2014 follow-up survey. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, S1-S14.	1.1	20
211	Pulmonary nodules in African migrants caused by chronic schistosomiasis. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e159-e165.	4.6	20
212	NGS barcode sequencing in taxonomy and diagnostics, an application in "Candida" pathogenic yeasts with a metagenomic perspective. <i>IMA Fungus</i> , 2018, 9, 91-105.	1.7	20
213	Management of vertebral osteomyelitis over an eight-year period: The UDIPROVE (UDine PROtocol on) Tj ETQq1 1 0.784314 ggBT /Overl 1.5	1.5	20
214	Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, ii5-ii14.	1.3	19
215	Exploring ecological modelling to investigate factors governing the colonization success in nosocomial environment of <i>Candida albicans</i> and other pathogenic yeasts. <i>Scientific Reports</i> , 2016, 6, 26860.	1.6	19
216	Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1193-1200.	1.5	19

#	ARTICLE	IF	CITATIONS
217	Ceftolozane/tazobactam for the treatment of MDR <i>Pseudomonas aeruginosa</i> left ventricular assist device infection as a bridge to heart transplant. <i>Infection</i> , 2018, 46, 263-265.	2.3	19
218	ECMM <i>Candi</i> Regâ€”A ready to use platform for outbreaks and epidemiological studies. <i>Mycoses</i> , 2019, 62, 920-927.	1.8	19
219	Hot topics in diabetic foot infection. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105942.	1.1	19
220	Factors associated with the development of septic shock in patients with candidemia: a post hoc analysis from two prospective cohorts. <i>Critical Care</i> , 2020, 24, 117.	2.5	19
221	Management of Infections Caused by Multidrug-resistant Gram-negative Pathogens: Recent Advances and Future Directions. <i>Archives of Medical Research</i> , 2021, 52, 817-827.	1.5	19
222	Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 346-350.	1.1	18
223	Determination of PCT on admission is a useful tool for the assessment of disease severity in travelers with imported <i>Plasmodium falciparum</i> malaria. <i>Acta Parasitologica</i> , 2016, 61, 412-8.	0.4	18
224	Multidrug-resistant <i>Pseudomonas aeruginosa</i> skin and soft-tissue infection successfully treated with ceftolozane/tazobactam. <i>Journal of Global Antimicrobial Resistance</i> , 2017, 9, 100-102.	0.9	18
225	Predictors of Mortality with <i>Staphylococcus aureus</i> Bacteremia in Elderly Adults. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1284-1289.	1.3	18
226	New Antibiotics for Pneumonia. <i>Clinics in Chest Medicine</i> , 2018, 39, 853-869.	0.8	18
227	Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106104.	1.1	18
228	The Impact of Carbapenem Resistance on Mortality in Patients With <i>Klebsiella Pneumoniae</i> Bloodstream Infection: An Individual Patient Data Meta-Analysis of 1952 Patients. <i>Infectious Diseases and Therapy</i> , 2021, 10, 541-558.	1.8	18
229	Pros and cons of liver transplantation in human immunodeficiency virus infected recipients. <i>World Journal of Gastroenterology</i> , 2014, 20, 5353.	1.4	18
230	Critically ill migrants with infection: diagnostic considerations for intensive care physicians in Europe. <i>Intensive Care Medicine</i> , 2016, 42, 245-248.	3.9	17
231	<i>Tedizolid phosphate</i> for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy. <i>Core Evidence</i> , 2019, Volume 14, 31-40.	4.7	17
232	Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 221, 356-366.	1.9	17
233	Treatment of severe infections due to metallo- β -lactamases-producing Gram-negative bacteria. <i>Future Microbiology</i> , 2020, 15, 1489-1505.	1.0	17
234	The Role of Dysbiosis in Critically Ill Patients With COVID-19 and Acute Respiratory Distress Syndrome. <i>Frontiers in Medicine</i> , 2021, 8, 671714.	1.2	17

#	ARTICLE	IF	CITATIONS
235	Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : a multicentre study. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac022.	0.9	17
236	Prognostic Impact of Bronchoalveolar Lavage Fluid Galactomannan and <i>Aspergillus</i> Culture Results on Survival in COVID-19 Intensive Care Unit Patients: a Post Hoc Analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-Associated Pulmonary Aspergillosis Study. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0229821.	1.8	17
237	Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, ii45-ii55.	1.3	16
238	New therapeutic options for skin and soft tissue infections. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 99-108.	1.3	16
239	Candidemia in Patients with Body Temperature Below 37°C and Admitted to Internal Medicine Wards: Assessment of Risk Factors. <i>American Journal of Medicine</i> , 2016, 129, 1330.e1-1330.e6.	0.6	16
240	Anidulafungin for the treatment of candidaemia caused by <i>Candida parapsilosis</i> : Analysis of pooled data from six prospective clinical studies. <i>Mycoses</i> , 2017, 60, 663-667.	1.8	16
241	Comparison between procalcitonin and C-reactive protein to predict blood culture results in ICU patients. <i>Critical Care</i> , 2018, 22, 252.	2.5	16
242	Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering. <i>Future Microbiology</i> , 2018, 13, 1081-1094.	1.0	16
243	Combating resistance while maintaining innovation: the future of antimicrobial stewardship. <i>Future Microbiology</i> , 2019, 14, 1331-1341.	1.0	16
244	Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant <i>Staphylococcus aureus</i> : advances in phase I and II trials. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 495-506.	1.9	16
245	Personal protective equipment use by healthcare workers in intensive care unit during the early phase of COVID-19 pandemic in Italy: a secondary analysis of the PPE-SAFE survey. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612199856.	1.1	16
246	Methicillin-resistant <i>Staphylococcus aureus</i> lung infection in coronavirus disease 2019: how common?. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 149-162.	1.3	16
247	Multidrug-resistant Gram-negative bacteria-resistant infections: epidemiology, clinical issues and therapeutic options. <i>Italian Journal of Medicine</i> , 2016, 10, 364.	0.2	15
248	When to switch to an oral treatment and/or to discharge a patient with skin and soft tissue infections. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 163-169.	1.3	15
249	Important new therapies for methicillin-resistant <i>Staphylococcus aureus</i> . <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2317-2334.	0.9	15
250	Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. <i>Clinical Infectious Diseases</i> , 2019, 68, S233-S240.	2.9	15
251	Brain microvascular occlusive disorder in COVID-19: a case report. <i>Neurological Sciences</i> , 2020, 41, 3401-3404.	0.9	15
252	Recent advances and future perspectives in the pharmacological treatment of <i>Candida auris</i> infections. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1205-1220.	1.3	15

#	ARTICLE	IF	CITATIONS
253	Infective endocarditis in elderly: An Italian prospective multi-center observational study. <i>International Journal of Cardiology</i> , 2014, 177, 636-638.	0.8	14
254	Machine Learning and Multidrug-Resistant Gram-Negative Bacteria: An Interesting Combination for Current and Future Research. <i>Antibiotics</i> , 2020, 9, 54.	1.5	14
255	Reactivation of Herpes Simplex Virus Type 1 (HSV-1) Detected on Bronchoalveolar Lavage Fluid (BALF) Samples in Critically Ill COVID-19 Patients Undergoing Invasive Mechanical Ventilation: Preliminary Results from Two Italian Centers. <i>Microorganisms</i> , 2022, 10, 362.	1.6	14
256	The Management of the Infected Diabetic Foot. <i>Current Diabetes Reviews</i> , 2013, 9, 7-24.	0.6	13
257	Risk factors associated with the onset of daptomycin non-susceptibility in <i>Staphylococcus aureus</i> infections in critically ill patients. <i>Intensive Care Medicine</i> , 2015, 41, 366-368.	3.9	13
258	Individualizing duration of antibiotic therapy in community-acquired pneumonia. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 45, 191-201.	1.1	13
259	Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 479-488.	1.1	13
260	Incremental value of FDG-PET/CT to monitor treatment response in infectious spondylodiscitis. <i>Skeletal Radiology</i> , 2020, 49, 903-912.	1.2	13
261	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. <i>Infectious Diseases and Therapy</i> , 2022, 11, 827-840.	1.8	13
262	The role of telavancin in the treatment of MRSA infections in hospital. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 521-529.	1.9	12
263	Treatment of <i>Candida</i> infections with fluconazole in adult liver transplant recipients: Is TDM-guided dosing adaptation helpful?. <i>Transplant Infectious Disease</i> , 2019, 21, e13113.	0.7	12
264	Risk scores and surgery for infective endocarditis: in search of a good predictive score. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 117-124.	0.4	12
265	A look at the clinical, economic, and societal impact of antimicrobial resistance in 2020. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2067-2071.	0.9	12
266	<p>Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam</p>. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 1763-1773.	1.1	12
267	Efficacy and safety of eravacycline: A meta-analysis. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 24, 424-428.	0.9	12
268	An Experimental Pre-Post Study on the Efficacy of Respiratory Physiotherapy in Severe Critically Ill COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 2139.	1.0	12
269	Early Effects of Passive Leg-Raising Test, Fluid Challenge, and Norepinephrine on Cerebral Autoregulation and Oxygenation in COVID-19 Critically Ill Patients. <i>Frontiers in Neurology</i> , 2021, 12, 674466.	1.1	12
270	Understanding the pathophysiology of typical acute respiratory distress syndrome and severe COVID-19. <i>Expert Review of Respiratory Medicine</i> , 2022, , 1-10.	1.0	12

#	ARTICLE	IF	CITATIONS
271	Current pharmacotherapy for methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) pneumonia. Expert Opinion on Pharmacotherapy, 2022, 23, 361-375.	0.9	12
272	Are prophylactic antifungals in highly colonized patients safe and effective?. Intensive Care Medicine, 2015, 41, 1336-1339.	3.9	11
273	Overview of Fungal Infections - The Italian Experience. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 796-806.	0.8	11
274	¹⁸ F-Fluorodeoxyglucose positron emission tomography and infectious diseases. Current Opinion in Infectious Diseases, 2017, 30, 192-200.	1.3	11
275	Estimated burden of fungal infections in Italy. Journal of Infection, 2018, 76, 103-106.	1.7	11
276	Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI). Antimicrobial Resistance and Infection Control, 2019, 8, 204.	1.5	11
277	Role of new antibiotics in the treatment of acute bacterial skin and skin-structure infections. Current Opinion in Infectious Diseases, 2020, 33, 110-120.	1.3	11
278	Characterisation and risk factor profiling of <i>Pseudomonas aeruginosa</i> urinary tract infections: pinpointing those likely to be caused by multidrug-resistant strains. International Journal of Antimicrobial Agents, 2020, 55, 105900.	1.1	11
279	Systemic fibrinolysis for acute pulmonary embolism complicating acute respiratory distress syndrome in severe COVID-19: a case series. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 78-80.	1.4	11
280	Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study. Infectious Diseases and Therapy, 2021, 10, 387-398.	1.8	11
281	Recent molecules in the treatment of severe infections caused by ESBL-producing bacteria. Expert Review of Anti-Infective Therapy, 2021, 19, 983-991.	2.0	11
282	The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. Expert Review of Anti-Infective Therapy, 2021, 19, 1125-1134.	2.0	11
283	A survey on infection management practices in Italian ICUs. Critical Care, 2012, 16, R221.	2.5	10
284	Linezolid underexposure in a patient co-treated with venlafaxine. European Journal of Clinical Pharmacology, 2015, 71, 1285-1286.	0.8	10
285	Daptomycin-containing regimens for treatment of Gram-positive endocarditis. International Journal of Antimicrobial Agents, 2019, 54, 423-434.	1.1	10
286	Should High-dose Daptomycin be an Alternative Treatment Regimen for Enterococcal Endocarditis?. Infectious Diseases and Therapy, 2019, 8, 695-702.	1.8	10
287	Prospective Study on Incidence, Risk Factors and Outcome of Recurrent <i>Clostridioides difficile</i> Infections. Journal of Clinical Medicine, 2021, 10, 1127.	1.0	10
288	Treatment of extended-spectrum β -lactamases infections: what is the current role of new β -lactams/ β -lactamase inhibitors?. Current Opinion in Infectious Diseases, 2020, 33, 474-481.	1.3	10

#	ARTICLE	IF	CITATIONS
289	Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e74-e87.	4.6	10
290	<i>Aspergillus</i> PCR in bronchoalveolar lavage diagnostic accuracy for invasive pulmonary aspergillosis in critically ill patients. <i>Mycoses</i> , 2022, 65, 411-418.	1.8	10
291	Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2522-2531.	1.3	10
292	New therapeutic options for respiratory tract infections. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 178-186.	1.3	9
293	Is first-line antimicrobial therapy still adequate to treat MRSA in the ICU? A report from a highly endemic country. <i>Critical Care</i> , 2016, 20, 246.	2.5	9
294	Prosthetic joints: shining lights on challenging blind spots. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 153-161.	1.1	9
295	How Should We Treat HAP/VAP Caused by Carbapenemase-Producing Enterobacteriaceae?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 301-310.	0.8	9
296	Emerging drugs for treating methicillin-resistant <i>Staphylococcus aureus</i> . <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 191-204.	1.0	9
297	Prosthetic joint infections. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 102-112.	1.3	9
298	Current role of oxazolidinones and lipoglycopeptides in skin and soft tissue infections. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 123-129.	1.3	9
299	Salvage heart transplantation for <i>Mycoplasma hominis</i> prosthetic valve endocarditis: A case report and review of the literature. <i>Transplant Infectious Disease</i> , 2020, 22, e13249.	0.7	9
300	Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105921.	1.1	9
301	In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	9
302	Role of new antibiotics in extended-spectrum β -lactamase-, AmpC- infections. <i>Current Opinion in Infectious Diseases</i> , 2021, Publish Ahead of Print, 748-755.	1.3	9
303	The role of new antimicrobials for Gram-negative infections in daily clinical practice. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 495-500.	1.3	9
304	SDD and colistin resistance: end of a dream?. <i>Intensive Care Medicine</i> , 2014, 40, 1066-1067.	3.9	8
305	MEDical wards Invasive Candidiasis ALgorithms (MEDICAL):Consensus proposal for management. <i>European Journal of Internal Medicine</i> , 2016, 34, 45-53.	1.0	8
306	Elderly versus non-elderly patients with intra-abdominal candidiasis in the ICU. <i>Minerva Anestesiologica</i> , 2017, 83, 1126-1136.	0.6	8

#	ARTICLE	IF	CITATIONS
307	Antipathy against SDD is justified: Yes. <i>Intensive Care Medicine</i> , 2018, 44, 1165-1168.	3.9	8
308	A look at clinical trial design for new antimicrobials for the adult population. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 1037-1046.	1.3	8
309	Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 266-269.	1.1	8
310	Higher Mortality and Intensive Care Unit Admissions in COVID-19 Patients with Liver Enzyme Elevations. <i>Microorganisms</i> , 2020, 8, 2010.	1.6	8
311	Clinical Features and Mortality of Nosocomial Candidemia in Very Old Patients: A Multicentre Italian Study. <i>Gerontology</i> , 2020, 66, 532-541.	1.4	8
312	Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy. <i>Clinical Therapeutics</i> , 2020, 42, 802-817.	1.1	8
313	Single Strain High-Depth NGS Reveals High rDNA (ITS-LSU) Variability in the Four Prevalent Pathogenic Species of the Genus <i>Candida</i> . <i>Microorganisms</i> , 2021, 9, 302.	1.6	8
314	Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care. <i>European Journal of Internal Medicine</i> , 2021, 94, 39-44.	1.0	8
315	Early versus late intubation in COVID-19 patients failing helmet CPAP: A quantitative computed tomography study. <i>Respiratory Physiology and Neurobiology</i> , 2022, 301, 103889.	0.7	8
316	Treatment of consecutive episodes of multidrug-resistant bacterial pleurisy with different aetiology in a heart transplant candidate: proof of concept of pharmacokinetic/pharmacodynamic optimisation of antimicrobial therapy at the infection site. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 570-571.	1.1	7
317	Issues in the management of invasive pulmonary aspergillosis in non-neutropenic patients in the intensive care unit: A role for isavuconazole. <i>IDCases</i> , 2018, 12, 7-9.	0.4	7
318	Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1671-1672.	0.8	7
319	Judging the appropriate therapy for carbapenem-resistant <i>Acinetobacter</i> infections. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 135-138.	0.9	7
320	Efficacy and Safety of Carbapenems vs New Antibiotics for Treatment of Adult Patients With Complicated Urinary Tract Infections: A Systematic Review and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofaa480.	0.4	7
321	Risk Factors for Candidemia After Open Heart Surgery: Results From a Multicenter Case-Control Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa233.	0.4	7
322	Role of oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 96-108.	1.3	7
323	Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian Tj ETQq1 1 0.784314 rgBT /Overlock 10 25, 346-350.	0.9	7
324	Clinical consequences of very major errors with semi-automated testing systems for antimicrobial susceptibility of carbapenem-resistant Enterobacterales. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1290.e1-1290.e4.	2.8	7

#	ARTICLE	IF	CITATIONS
325	Innovative β -lactam/ β -lactamase inhibitor combinations for carbapenem-resistant Gram-negative bacteria. <i>Future Microbiology</i> , 2022, 17, 393-396.	1.0	7
326	Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections and Bloodstream Infections Caused by <i>Staphylococcus aureus</i> : A Comprehensive Review of the Evidence. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 2137-2157.	1.1	7
327	Is empiric daptomycin effective in reducing mortality in <i>Staphylococcus aureus</i> bacteraemia? A real-life experience. <i>Intensive Care Medicine</i> , 2015, 41, 2026-2028.	3.9	6
328	“Salvage treatment” for infections by extensively- and pan-drug-resistant pathogens is common and often sub-optimal. <i>Intensive Care Medicine</i> , 2017, 43, 1164-1166.	3.9	6
329	Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review. <i>Journal of NeuroVirology</i> , 2017, 23, 908-912.	1.0	6
330	Epidemiological and clinical features of imported malaria at the three main hospitals of the Friuli-Venezia Giulia Region, Italy. <i>Infection, Disease and Health</i> , 2018, 23, 17-22.	0.5	6
331	Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with <i>Candida albicans</i> and non- <i>albicans</i> spp.. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1449-1459.	0.8	6
332	KPC-producing <i>Klebsiella pneumoniae</i> gut decolonisation following ceftazidime/avibactam-based combination therapy: A retrospective observational study. <i>Journal of Global Antimicrobial Resistance</i> , 2019, 17, 109-111.	0.9	6
333	Use of Ceftaroline in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional Study. <i>Antibiotics</i> , 2021, 10, 763.	1.5	6
334	New antibiotics for the treatment of nonfermenting Gram-negative bacteria. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 701-709.	1.3	6
335	Potential role of new-generation antibiotics in acute bacterial skin and skin structure infections. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 109-117.	1.3	6
336	Long course of daptomycin in the treatment of meticillin-resistant <i>Staphylococcus epidermidis</i> endocarditis and spondylodiscitis. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 290-291.	1.1	5
337	Management of patients with septic shock due to <i>Candida</i> infection. <i>Hospital Practice (1995)</i> , 2018, 46, 258-265.	0.5	5
338	Antibiotic treatment of acute bacterial skin and skin structure infections. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 120-127.	1.3	5
339	Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 963-979.	2.0	5
340	The Use of Different Components of Brain Oxygenation for the Assessment of Cerebral Haemodynamics: A Prospective Observational Study on COVID-19 Patients. <i>Frontiers in Neurology</i> , 2021, 12, 735469.	1.1	5
341	“Excess Mortality” and Colistin-Tigecycline for Extensively Drug-Resistant <i>Acinetobacter baumannii</i> Bacteremia. <i>Critical Care Medicine</i> , 2015, 43, e470-e471.	0.4	4
342	An Evaluation of the Effectiveness of Risk Minimization Measures for Tigecycline in the European Union. <i>Pharmaceutical Medicine</i> , 2017, 31, 89-99.	1.0	4

#	ARTICLE	IF	CITATIONS
343	The most recent concepts for the management of bacterial and fungal infections in ICU. Intensive Care Medicine, 2018, 44, 2000-2003.	3.9	4
344	Update on epidemiology and appropriate treatment of life-threatening gram-negative infections. Current Opinion in Infectious Diseases, 2018, 31, 553-554.	1.3	4
345	Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?. Journal of Global Antimicrobial Resistance, 2018, 14, 238-241.	0.9	4
346	Immunological profiles of HIV-positive recipients of liver transplant. Transplant Immunology, 2019, 57, 101208.	0.6	4
347	High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection. European Journal of Clinical Investigation, 2020, 50, e13358.	1.7	4
348	Neuroinvasive West Nile Infection with an Unusual Clinical Presentation: A Single-Center Case Series. Tropical Medicine and Infectious Disease, 2020, 5, 138.	0.9	4
349	COVID-19: Some clinical questions after the first 4 months. European Journal of Clinical Investigation, 2020, 50, e13326.	1.7	4
350	Antimicrobial de-escalation is part of appropriate antibiotic usage in ICU. Intensive Care Medicine, 2020, 46, 1039-1042.	3.9	4
351	The COVID-19 insidious trick: Subjective perception of numbers. European Journal of Clinical Investigation, 2021, 51, e13465.	1.7	4
352	Antiviral treatment selection for SARS-CoV-2 pneumonia. Expert Review of Respiratory Medicine, 2021, 15, 985-992.	1.0	4
353	Placing in-vitro heteroresistance in the context of clinical results. Lancet Infectious Diseases, The, 2021, 21, 908-909.	4.6	4
354	How do we optimize the prescribing of intravenous polymyxins to increase their longevity and efficacy in critically ill patients?. Expert Opinion on Pharmacotherapy, 2022, 23, 5-8.	0.9	4
355	Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 132-137.	0.9	4
356	Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia. Expert Review of Anti-Infective Therapy, 2022, 20, 649-656.	2.0	4
357	Development of antibiotics for Gram-negatives: where now?. Clinical Investigation, 2011, 1, 211-227.	0.0	3
358	Treatment and mortality of Klebsiella pneumoniae infections in critically ill patients: should we do and predict them better?. Intensive Care Medicine, 2018, 44, 1982-1984.	3.9	3
359	Conventional amphotericin B must be avoided in Candida infections. Intensive Care Medicine, 2020, 46, 560-561.	3.9	3
360	A very rare case of mycobacterium gordonae infection of the breast. Breast Journal, 2020, 26, 2229-2232.	0.4	3

#	ARTICLE	IF	CITATIONS
361	The Importance of Quantitative Results of a Lateral Flow Aspergillus Assay: The Significant Impact on Specificity. <i>Clinical Infectious Diseases</i> , 2020, 73, e1783-e1784.	2.9	3
362	The interplay between acute bacterial skin and skin structure infections and depression. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 1.	1.3	3
363	Comparison of the Safety and Tolerance Profile of Micafungin with that of Other Echinocandins and Azoles in Patients with Pre-existing Childâ€Pugh B or C Liver Disease: A Caseâ€Control Retrospective Study. <i>Infectious Diseases and Therapy</i> , 2020, 9, 151-163.	1.8	3
364	Will vaccine hesitancy compromise our efforts to face the next SARS-CoV-2 epidemic wave?. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1664-1665.	1.4	3
365	Performance of Existing Definitions and Tests for the Diagnosis of Invasive Fungal Diseases other than Invasive Candidiasis and Invasive Aspergillosis in Critically Ill, Adult Patients: A Systematic Review with Qualitative Evidence Synthesis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 176.	1.5	3
366	A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic. <i>Drugs in Context</i> , 2020, 9, 1-2.	1.0	3
367	A new call for influenza and pneumococcal vaccinations during COVID-19 pandemic in Italy: a SIP/IRS (Italian Respiratory Society) and SITA (Italian Society of Antiinfective therapy) statement. <i>Respiratory Medicine</i> , 2021, 190, 106674.	1.3	3
368	Improving management and antimicrobial stewardship for bacterial and fungal infections in hospitalized patients with COVID-19. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612210957.	1.1	3
369	Principles of antimicrobial stewardship for bacterial and fungal infections in ICU. <i>Intensive Care Medicine</i> , 2017, 43, 1894-1897.	3.9	2
370	Candida endocarditis and the impact of antifungal treatment on the corrected QT interval: a case report. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 402-403.	0.3	2
371	A prognostic score for the resolution of bacteremia by Gram-negative bacteria resistant to carbapenems. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2083-2089.	1.3	2
372	Influence of age on the clinical efficacy of tigecycline in severely ill patients. <i>Journal of Global Antimicrobial Resistance</i> , 2019, 18, 199-206.	0.9	2
373	Surgical Complications Requiring an Early Relaparotomy in HIV-Infected Liver Transplant Recipients: Risk Factors and Impact on Survival. <i>Transplantation Proceedings</i> , 2019, 51, 2977-2980.	0.3	2
374	Enriching the antibiotic armamentarium for acute bacterial skin and skin structure infections. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1037-1039.	4.6	2
375	Serological and T Cell Responses After Varicella Zoster Virus Vaccination in HIV-Positive Patients Undergoing Renal Dialysis. <i>Viral Immunology</i> , 2019, 32, 151-157.	0.6	2
376	Early postâ€liver transplant surgical morbidity in HIV-infected recipients: risk factor for overall survival? A nationwide retrospective study. <i>Transplant International</i> , 2019, 32, 1044-1052.	0.8	2
377	Viremia copy-years and risk of estimated glomerular filtration rate reduction in adults living with perinatal HIV infection. <i>PLoS ONE</i> , 2020, 15, e0240550.	1.1	2
378	Adequate duration of therapy in severe fungal infections. <i>Current Opinion in Critical Care</i> , 2020, 26, 466-472.	1.6	2

#	ARTICLE	IF	CITATIONS
379	A Wide Database for Future Studies Aimed at Improving Early Recognition of Candidemia. <i>Studies in Health Technology and Informatics</i> , 2021, 281, 1081-1082.	0.2	2
380	The Role of PCSK9 in Infectious Diseases. <i>Current Medicinal Chemistry</i> , 2022, 29, 1000-1015.	1.2	2
381	Complicated carbapenem-resistant infections: a treatment pathway analysis in Italian sites. <i>Infezioni in Medicina</i> , 2021, 29, 434-449.	0.7	2
382	Clinical significance of inflammatory markers of bacterial infection in critically ill patients with COVID-19 after treatment with anti-inflammatory and immunomodulatory drugs: a complex new scenario. <i>Frontiers in Bioscience</i> , 2021, 26, 405.	0.8	2
383	Safety evaluation of current therapies for high-risk severely ill patients with carbapenem-resistant infections. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 487-498.	1.0	2
384	Beta Lactams Plus Daptomycin Combination Therapy for Infective Endocarditis: An Italian National Survey (BADAS). <i>Antibiotics</i> , 2022, 11, 56.	1.5	2
385	Levels of beta-D-glucan in <i>Candida auris</i> supernatants, an <i>in vitro</i> and <i>in vivo</i> preliminary study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1154.e1-1154.e3.	2.8	2
386	Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study. <i>Multiple Sclerosis Journal</i> , 2023, 29, 481-482.	1.4	2
387	Fungal Endogenous Endophthalmitis Secondary to <i>Magnusiomyces capitatus</i> . <i>Case Reports in Ophthalmology</i> , 2019, 10, 292-298.	0.3	1
388	Valuing antibiotics: The role of the hospital clinician. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 16-22.	1.1	1
389	Management of reduced vaccine coverage due to 6 years of failure to vaccinate: The Codroipo case, Italy. <i>Vaccine</i> , 2019, 37, 2294-2297.	1.7	1
390	Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain. <i>Journal of Medical Economics</i> , 2020, 23, 148-155.	1.0	1
391	<i>Saprochaete capitata</i> aortitis in an immunocompetent patient after myocardial revascularization. <i>Cardiovascular Pathology</i> , 2020, 48, 107223.	0.7	1
392	Role of Antifungal Therapy in Complicated Intra-abdominal Infections. <i>Current Infectious Disease Reports</i> , 2020, 22, 1.	1.3	1
393	Editorial: Spotlight on the Relationship Between Sepsis and Infection: From Mechanisms to Therapy. <i>Frontiers in Medicine</i> , 2021, 8, 716215.	1.2	1
394	A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Infectious Diseases and Therapy</i> , 2022, 11, 635-638.	1.8	1
395	<i>Mycobacterium tuberculosis</i> Surgical Site Infection after Cardiac Surgery in the COVID-19 Era: A Case Report. <i>Infectious Disease Reports</i> , 2022, 14, 101-105.	1.5	1
396	Factors Associated with Inadequate Intravenous Colistin Dosages: Post Hoc Analysis of a Multicenter, Cross-Sectional Study. <i>Antibiotics</i> , 2021, 10, 1554.	1.5	1

#	ARTICLE	IF	CITATIONS
397	A Wide Database for a Multicenter Study on Pneumocystis jirovecii Pneumonia in Intensive Care Units. Studies in Health Technology and Informatics, 2022, , .	0.2	1
398	Update on new research in Gram-negative infections European Congress of Clinical Microbiology and Infectious Diseases 2017 (22â€“25 April, Vienna, Austria). Future Science OA, 2018, 4, FSO270.	0.9	0
399	The current role of glycopeptides in the treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts. Journal of Chemotherapy, 2018, 30, 157-171.	0.7	0
400	Update on skin and soft tissue infections. Current Opinion in Infectious Diseases, 2018, 31, 103.	1.3	0
401	An introduction to the future of echinocandin therapy. Journal of Antimicrobial Chemotherapy, 2018, 73, i2-i3.	1.3	0
402	Reducing dissemination of carbapenem-resistant Klebsiella pneumoniae. Annals of Translational Medicine, 2019, 7, S365-S365.	0.7	0
403	Response. Chest, 2021, 159, 1677-1678.	0.4	0
404	Drugs in Context Editorial: Review of 2020 and what lies ahead in therapeutic interventions. Drugs in Context, 2021, 10, 1-5.	1.0	0
405	Early infections after successful transcatheter aortic valve replacement are associated with increased short- and long-term mortality: A single-center study. International Journal of Cardiology, 2021, 332, 48-53.	0.8	0
406	Diabetic Foot Team. , 2014, , 1-40.		0
407	Diabetic Foot Team. , 2015, , 4923-4955.		0
408	Overcoming Antibiotic Resistance: New Perspectives. Human Perspectives in Health Sciences and Technology, 2020, , 457-480.	0.2	0
409	Re: time to blood culture positivity in Staphylococcus aureus bacteraemia to determine risk of infective endocarditis. Clinical Microbiology and Infection, 2022, , .	2.8	0
410	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. , 2020, 15, e0237831.		0
411	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. , 2020, 15, e0237831.		0